Vaccine · Immune activation · developed by Bavarian Nordic
ApprovedFDA, Sep 2019
2Registered trials
What is MVA-BN?
MVA-BN is a live, attenuated, non-replicating modified vaccinia Ankara vaccine that induces cellular and humoral immune responses. It is studied for the prevention of smallpox and mpox (monkeypox).
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.